• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

    11/23/22 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email

    Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan currently serves as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, a global medical device company, and Mr. Vergnano is the former Chairman, President and Chief Executive Officer of The Chemours Company, a chemistry company.

    "Dan and Mark are outstanding leaders whose decades of experience in the medical device and chemistry industries will add tremendous value as Waters continues to execute its exciting growth strategy," said Dr. Flemming Ornskov, Chairman of the Board. "These appointments follow a robust search and build on the work we have done to refresh our Board, with five individuals joining over the last five years. We look forward to benefitting from Mark's and Dan's financial and operational expertise."

    "With a reinvigorated innovation engine and growth initiatives that continue to gain traction, we are excited to welcome two new directors to our Board whose expertise will support our strong and growing momentum," said Dr. Udit Batra, CEO and President, Waters Corporation. "Both Dan and Mark are experienced board members who have overseen highly dynamic companies and I am looking forward to collaborating with them. Dan brings two decades of finance leadership at Boston Scientific, where he oversaw successful margin and revenue growth initiatives. Mark brings deep operational expertise having led global sciences companies through transformations and significant periods of growth."

    "I am honored to join the Board of Waters, which has a strong reputation for innovation and leadership in life sciences," said Mr. Brennan.

    "Waters has undertaken a comprehensive and impressive transformation to position the Company for growth, and I am excited to contribute to the Board at this important time," said Mr. Vergnano.

    The addition of Mr. Brennan and Mr. Vergnano is part of the Board's ongoing refreshment process. With these appointments, the Board will expand to nine members, eight of whom are independent and five of whom have been appointed in the last five years.

    In his current role as Executive Vice President and Chief Financial Officer of Boston Scientific Corporation, Mr. Brennan is responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development. Prior to that, he was the company's Senior Vice President and Corporate Controller and held other roles of increasing responsibility within finance. He holds a B.S. in Finance and Investments and an M.B.A from Babson College and is also a certified public accountant.

    Mr. Vergnano currently serves as a Partner at Sea Shell Partners. He previously served as the Chairman, President and Chief Executive Officer of The Chemours Company. Prior to that, he held roles of increasing responsibility at E.I. Dupont De Nemours & Company, culminating in his role as Executive Vice President. Mr. Vergnano received a B.S. from the University of Connecticut and an M.B.A. from Virginia Commonwealth University. He currently serves on the Board of Johnson Controls International.

    Additional Resources

    • See list of the Waters Board of Directors
    • Connect with Waters via Twitter, Facebook and LinkedIn

    About Waters Corporation (www.waters.com)

    Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

    Waters is a trademark of Waters Corporation.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005848/en/

    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    2/10/2026$360.00In-line
    Evercore ISI
    2/10/2026$425.00Buy
    Citigroup
    2/10/2026$400.00Overweight
    Barclays
    1/6/2026$440.00Buy
    Guggenheim
    1/5/2026Outperform
    William Blair
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    12/2/2025$423.00Equal-Weight
    Morgan Stanley
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fraser Claire claimed ownership of 131 shares (SEC Form 3)

    3 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/18/26 4:15:11 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP, Waters Division Carpio Robert L Iii covered exercise/tax liability with 38 shares, decreasing direct ownership by 1% to 2,618 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/6/26 7:34:54 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP TA Instruments Division Bennett Jianqing was granted 1,385 shares and covered exercise/tax liability with 43 shares, increasing direct ownership by 27% to 6,258 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    2/6/26 7:33:43 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on Waters with a new price target

    Evercore ISI resumed coverage of Waters with a rating of In-line and set a new price target of $360.00

    2/10/26 8:10:12 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Barclays resumed coverage on Waters with a new price target

    Barclays resumed coverage of Waters with a rating of Overweight and set a new price target of $400.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup resumed coverage on Waters with a new price target

    Citigroup resumed coverage of Waters with a rating of Buy and set a new price target of $425.00

    2/10/26 8:03:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    SEC Form S-8 filed by Waters Corporation

    S-8 - WATERS CORP /DE/ (0001000697) (Filer)

    2/23/26 4:16:33 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-K filed by Waters Corporation

    10-K - WATERS CORP /DE/ (0001000697) (Filer)

    2/23/26 9:10:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - WATERS CORP /DE/ (0001000697) (Filer)

    2/9/26 4:16:29 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Corporation to Present at the TD Cowen Health Care Conference

    MILFORD, Mass., Feb. 23, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen Health Care Conference on Monday, March 2nd, 2026, at 11:10 AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days.About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatic

    2/23/26 4:45:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

    Headlines:Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1 Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2 Reduces solvent consumption by up to 4× versus 2.1 mm I.D. columns, helping laboratories meet sustainability goals, lower operating costs, and accelerate time to results without compromising performance. 2 MILFORD, Mass., Feb. 17, 2026 /CNW/ -- Waters Corporation (NYSE:WAT) today launched 1 mm I.D. liquid chroma

    2/17/26 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses

    Announces appointment of Claire M. Fraser, Ph.D., to its Board of DirectorsForms a global life sciences and diagnostics leader focused on high-volume testing in regulated applicationsAnnounces formation of four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials SciencesMILFORD, Mass., Feb. 9, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) ("Waters") today announced it has completed the previously announced combination with the Biosciences & Diagnostic Solutions businesses of Becton, Dickinson and Company (NYSE:BDX) ("BD"). The transaction forms a global life sciences and diagnostics leader, equipped with best-in-class technologies

    2/9/26 8:40:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results

    Highlights Fourth Quarter 2025 Sales of $932 million landed at the high-end of reported sales growth guidance range; grew 7% as reported and 6% in constant currencyGrowth led by high single-digit constant currency growth in Pharma and Industrial end-markets, with broad-based growth across all regionsChemistry grew 12% in constant currency as new bioseparations products continued to experience significant customer demandInstruments grew 3% in constant currency, with high single-digit LC-MS growth partially offset by TA and transition to subscription model for EmpowerGAAP EPS of $3.77; non-GAAP EPS of $4.53 grew double digitsFull-Year 2025 Sales of $3,165 million grew 7% as reported and 7% in

    2/9/26 6:30:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business

    Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE:BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters. 

    1/27/26 9:25:00 AM ET
    $BDX
    $WAT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Jan. 20, 2026 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q4 2025 financial results conference call on Thursday, February 12th, 2026 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least March 12, 2026, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety o

    1/20/26 1:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials